ReviewPharmaceutical research2009
Immunological risk of injectable drug delivery systems.
Review in Pharmaceutical research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 91 citations in OpenAlex.
- Decoy oligonucleotide technology in cancer therapy: molecular mechanisms, challenges, and translational potential.Medical oncology (Northwood, London, England) · 2026Review
- Antitumor efficacy and reduced systemic toxicity of palmitic acid-modified pirarubicin nanoparticles in mice.Cancer chemotherapy and pharmacology · 2026Article
- Advanced Platelet-Rich Fibrin (A-PRF) as Antibiotics Delivery System: In-Vitro Proof-of-Concept Study.Materials (Basel, Switzerland) · 2025Article
- Immunogenicity risk assessment for tailored mitigation and monitoring of biotherapeutics during development: recommendations from the European Immunogenicity Platform.Frontiers in immunology · 2025Review
- Strategies for overcoming protein and peptide instability in biodegradable drug delivery systems.Advanced drug delivery reviews · 2023Review
- The Therapeutic Potential of Chemo/Thermotherapy with Magnetoliposomes for Cancer Treatment.Pharmaceutics · 2022Review
- Review
- Type 1 diabetes and engineering enhanced islet transplantation.Advanced drug delivery reviews · 2022Review
- The Influence of Magnetic Composite Capsule Structure and Size on Their Trapping Efficiency in the Flow.Molecules (Basel, Switzerland) · 2022Article
- Local delivery strategies to restore immune homeostasis in the context of inflammation.Advanced drug delivery reviews · 2021Review
- Escaping to silence using an endosome-disrupting polymer.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Article
- Connecting primitive phase separation to biotechnology, synthetic biology, and engineering.Journal of biosciences · 2021Review
- Extracellular Vesicles-Based Drug Delivery Systems: A New Challenge and the Exemplum of Malignant Pleural Mesothelioma.International journal of molecular sciences · 2020Review
- Oral and Intra-nasal Administration of Nanoparticles in the Cerebral Ischemia Treatment in Animal Experiments: Considering its Advantages and Disadvantages.Current clinical pharmacology · 2020Review
- How the Lack of Chitosan Characterization Precludes Implementation of the Safe-by-Design Concept.Frontiers in bioengineering and biotechnology · 2020Review
- Polymeric Approaches to Reduce Tissue Responses Against Devices Applied for Islet-Cell Encapsulation.Frontiers in bioengineering and biotechnology · 2019Review
- Liposomes Loaded with Cisplatin and Magnetic Nanoparticles: Physicochemical Characterization, Pharmacokinetics, and In-Vitro Efficacy.Molecules (Basel, Switzerland) · 2018Article
- The accelerated blood clearance phenomenon of PEGylated nanoemulsion upon cross administration with nanoemulsions modified with polyglycerin.Asian journal of pharmaceutical sciences · 2018Article
- Stabilization of proteins in solid form.Advanced drug delivery reviews · 2015Review
- Emergence and Utility of Nonspherical Particles in Biomedicine.Industrial & engineering chemistry research · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Injectable drug delivery systems (DDS) such as particulate carriers and water-soluble polymers are being used and developed for a wide variety of therapeutic applications. However, a number of immunological risks with serious clinical implications are associated with administration of DDS. These immunological events can compromise the efficacy and safety of these systems by changing the pharmacokinetics, biodistribution and targeting capability of DDS, and by inducing hypersensitivity reactions. Antibodies induced by administration of DDS can be directed against the carrier material, the drug and/or targeting ligands associated with the DDS. Complement activation and opsonization of DDS, which may or may not be associated with antibody formation, may lead to accelerated clearance, hypersensitivity reactions and formation of membrane attack complexes resulting in premature release of the drug. Also platelets have been reported to play a role in DDS immunogenicity. Despite our curtailed understanding of the relationships between physicochemical characteristics and immunogenicity of DDS, several risk factors have been identified. Insight into these factors should be employed in the development of novel DDS with low immunological risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.